Abstract:The coronavirus disease 2019 (COVID-19) posed unprecedented challenges to health care systems worldwide, necessitating comprehensive research efforts to gain a better understanding of its diverse clinical presentations and associated complications. Among the numerous consequences of infection with the severe acute respiratory syndrome coronavirus 2, venous thromboembolism stands out as a critical concern, significantly contributing to both the morbidity and mortality of individuals hospitalized with COVID-19.[1] [2] Whole blood viscosity (WBV) serves as a validated measure of the resistance to shear stress encountered during blood flow within the circulatory system. Several studies have directly assessed WBV in COVID-19 patients and consistently reported elevated values when compared with uninfected individuals.[3] [4] Alterations in blood viscosity can influence microcirculation, exacerbate inflammation, and potentiate thrombosis, thereby playing a pivotal role in the pathogenesis of COVID-19-associated thromboembolic complications.[5] In retrospective cohort studies of hospitalized COVID-19 patients, increased high-shear and low-shear blood viscosity were significantly associated with higher in-hospital mortality and poor prognosis.[6] [7] Specifically, a 1 centipoise rise in high-shear viscosity was linked to a 36% increased risk of death ( p < 0.001),[7] and there was a decreased likelihood of being respiratory organ support-free at 21 days, with an odds ratio (OR) of 0.68 ( p < 0.001).[6] The Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC; NCT04372589) and A Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic Strategies in Hospitalized Adults with COVID-19 (ACTIV-4a; NCT04505774) platforms investigated therapeutic strategies to mitigate the thrombotic risk associated with COVID-19.[8] [9] These platforms reported improved survival and clinical outcomes with therapeutic-dose anticoagulation among noncritically ill patients with COVID-19, but not among those with critical illness. In this context, we conducted a post hoc analysis to explore the relationship between WBV and thromboembolic events in hospitalized patients with COVID-19. The study design and primary results of the trial has been previously published.[8] [9] The study received approval from the ethics committee and written or oral informed consent was obtained from all participants or their surrogates. Hospitalized patients with COVID-19 were enrolled in the trial. Exclusion criteria included patients with an imminent risk of death, a high risk of bleeding, those receiving dual antiplatelet therapy, individuals with a separate clinical indication for therapeutic-dose anticoagulation, or a history of heparin-induced cytopenia. Detailed exclusion criteria were published in a previous study.[8] [9] Estimated blood viscosity was calculated using the Walburn–Schneck model, which has been previously validated in a study involving COVID-19 patients.[10] [11] [12] The primary outcome of interest was composite outcome of 90-day mortality, venous thromboembolism events, and arterial thromboembolism events. Based on the calculated high-shear and low-shear blood viscosity values, participants were categorized into high- and low-blood viscosity groups using the median value. We used chi-square tests for categorical variables and t -tests for continuous variables to assess statistical significance between the high- and low-blood viscosity groups. Multivariable logistic regression was then conducted to determine ORs and their corresponding 95% confidence intervals (CIs) for the primary outcomes. Considered covariates were age, sex and oxygen requirement at presentation. All analyses were performed using SAS 9.4. We considered p -values less than 0.05 as statistically significant, and all p -values were evaluated using two-tailed tests. Baseline characteristics of the study population are presented in [Table 1]. Participants with higher blood viscosity were more likely to be male, of White or Hispanic ethnicity, younger in age, and had fewer comorbidities compared with those with lower blood viscosity. [Table 2] shows the associated of blood viscosity and primary outcome. A total of 149 primary composite outcome events were identified with a total event rate of 15.7%. However, COVID-19 patients with higher high-shear blood viscosity did not exhibit significantly different odds of developing the primary composite outcome (OR: 0.72, 95% CI: 0.51–1.02, p = 0.07). Variables High-shear BV lower half High-shear BV upper half p -Value BV range, cP 1.90–2.93 2.94–4.37 Severity status (%) 0.074 Seve -Abstract Truncated-

Whole Blood Viscosity and Thromboembolic Events in Hospitalized Patients with COVID-19: Post hoc Analysis of the ATTACC/ACTIV-4a Trial

Hemorrhage and Venous Thromboembolism in Critically Ill Patients with COVID-19

SARS-CoV-2 Induced Thrombocytopenia As an Important Biomarker Significantly Correlated with Abnormal Coagulation Function, Increased Intravascular Blood Clot Risk and Mortality in COVID-19 Patients

The Association of Anticoagulation Intensity with Outcomes in Hospitalized COVID-19 Patients

Prevalence of Low Limb Venous Thromboembolic Events in Mild and Severe/Critically Ill Patients with COVID-19 Despite Pharmacological Thromboprophylaxis

Death and Venous Thromboembolism Analyses among Hospitalized COVID-19-Positive Patients: A Multicenter Study

Incidence of Thrombosis in COVID-19 Patients Compared to Non-COVID-19 Sepsis Patients in the Intensive Care Unit

Effect of anticoagulation on the incidence of venous thromboembolism, major bleeding, and mortality among hospitalized COVID-19 patients: an updated meta-analysis

Racial Disparities in the Risk for Thromboembolic Events in COVID-19 Patients during the Height of the SARS-CoV-2 Pandemic and Impact on Outcomes

Thrombotic Events in COVID-19 Are Associated With a Lower Use of Prophylactic Anticoagulation Before Hospitalization and Followed by Decreases in Platelet Reactivity

Abstract WP260: Higher Incidence of Cerebral Venous Thrombosis Seen During the First Year of the COVID-19 Pandemic: Insights From the National Inpatient Sample

Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus Disease 2019

COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection

The Role of D-Dimer for Optimal Thromboprophylaxis Strategy in Patients with COVID-19

Pharmacologic Thromboprophylaxis and Thrombosis in Hospitalized Patients with COVID-19: A Pooled Analysis

Association of COVID-19 With Major Arterial and Venous Thrombotic Diseases: A Population-Wide Cohort Study of 48 Million Adults in England and Wales

Day‐by‐day Blood Pressure Variability in Hospitalized Patients with COVID‐19

Factors Associated With Risk of Postdischarge Thrombosis in Patients With COVID-19

Altered pulmonary blood volume distribution as a biomarker for predicting outcomes in COVID-19 disease

Incidence of Venous Thromboembolism and Mortality in Patients with Initial Presentation of COVID-19

Effects of inflammation on thrombosis and outcomes in COVID-19: secondary analysis of the ATTACC/ACTIV-4a trial